Boche, Delphine, Donald, Jane, Love, Seth, Harris, Scott, Neal, James W., Holmes, Clive, Nicoll, James A. R.

Alzheimer’s disease (AD) pathology is characterised by aggregation in the brain of amyloid-beta (Abeta) peptide and hyperphosphorylated tau (phospho-tau), although how these proteins interact in disease pathogenesis is unclear. Abeta immunisation results in removal of Abeta from the brain but cognitive decline continues to progress, possibly due to persistent phospho-tau. We quantified phospho-tau and Abeta42 […]

Relkin, Norman R., Szabo, Paul, Adamiak, Basia, Burgut, Tuna, Monthe, Carmen, Lent, Richard W., Younkin, Steven, Younkin, Linda, Schiff, Richard, Weksler, Marc E.

Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. […]

Vellas, Bruno, Black, R., Thal, Leon J., Fox, Nick C., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., Grundman, Michael

Background: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid-beta peptide (Abeta(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery […]